Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis-Reference-Cited by-同舟云学术

Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis

Published:2022-01 Issue:1 Volume:22 Page:e21-e29
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Dong Liangliang,Lin Shen,Zhong Lixian,Nian Dongni,Li Yiyuan,Wang Rixiong,Zhou Wei,Weng Xiuhua,Xu Xiongwei

Funder

National Natural Science Foundation of China

Natural Science Foundation of Fujian Province

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. The International Agency for Research on Cancer of World Health Organization. Latest global cancer data:cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. Available at: https://www.iarc.fr/faq/latest-global-cancer-data-2020-qa/; 2020 Accessed December 15, 2020.

2. Cancer statistics, 2021;Siegel;CA Cancer J Clin,2021

3. Breast cancer statistics, 2019;DeSantis;CA Cancer J Clin,2019

4. Disease-free and overall survival among patients with operable HER2-positive breast cancer treated with sequential vs concurrent chemotherapy: the ACOSOG Z1041 (Alliance) randomized clinical trial;Buzdar;JAMA Oncol,2019

5. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial;Lin;J Clin Oncol,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration;European Journal of Medicinal Chemistry;2023-12

2. Cost‐effectiveness analysis of tislelizumab in combination with chemotherapy for the first‐line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China;Head & Neck;2023-10-17

3. First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis;Orphanet Journal of Rare Diseases;2023-10-16

4. First-line Nivolumab Plus Ipilimumab for Unresectable MPM in China: a Cost-effectiveness Analysis;2023-05-19

5. Financial toxicity of radiotherapy for multiple brain metastases: Will it get worse or better?;Neuro-Oncology Practice;2023-04-14